TERP API - Nanology Labs
Alternative Names: TERP-APILatest Information Update: 30 Sep 2022
At a glance
- Originator Nanology Labs
- Developer QurCan Therapeutics
- Class Antineoplastics; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Solid tumours
Most Recent Events
- 26 Aug 2021 TERP API - Nanology Labs is available for licensing as of 26 Aug 2021. https://www.nanologylabs.com/pipeline.html
- 26 Aug 2021 Preclinical trials in Alzheimer's in USA (Parentral) (QurCan therapeutics pipeline Oct 2022)
- 26 Aug 2021 Preclinical trials in Solid tumours in USA (Parentral) prior to August 2021 (Nanology Labs pipeline, August 2021)